Quanta to Participate in Upcoming Virtual Investor Conferences
ALCESTER, United Kingdom, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology innovation company, today announces that management will be participating in three upcoming investor conferences.
Details of the virtual conferences are as follows:
Jefferies London Healthcare Conference, November 17-19, 2020
Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum, November 19, 2020
Piper Sandler 32nd Annual Healthcare Conference, November 30 - December 3, 2020
For more information about Quanta, please contact:
About Quanta and SC+
SC+ is CE Marked and commercially available in the UK, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The unobtrusive, simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.
For more information, please visit our website: quantadt.com
SC+ is not yet FDA cleared and not yet available for sale or use in the USA.